The senior director and global compound development team leader at Janssen talked about the importance of biomarkers in detecting an earlier diagnosis of myasthenia gravis and the significant unmet medical need for better treatment options. [WATCH TIME: 3 minutes]
David Greeley, MD, chief medical officer at AriBio and study author, provided commentary on the mechanism of action of AR1001, its promising effect on ptau181, and the next steps in its development.
The vice-chair for research at Cleveland Clinic’s Neurological Institute discussed the way therapies are currently assessed for progressive MS and the need for disease-specific biomarkers. [WATCH TIME: 3 minutes]
Recent research has suggested a role for thyroid hormones and their receptor, thyrotropin, in muscle regeneration and development, making a case for further investigation in DMD.
Presented at the 2023 World Sleep Congress, preclinical findings highlighted ORX750's potential as a novel treatment not only for narcolepsy type 1 but also for broader sleep-wake disorders, including narcolepsy type 2 and idiopathic hypersomnia.
Over a 52-week treatment period, SRP-9001 demonstrated robust evidence for a clinically meaningful benefit across several prespecified functional secondary end points in comparison with placebo.
Jeffrey Cohen, MD; Sarah Anderson, PharmD, NBC-HWC; and Alicyn Magruder, PharmD, BCACP, MSCS, share their final thoughts on the future landscape of clinical MS care in the biosimiliars era. [WATCH TIME: 12 minutes]
In a sample of more than 750 patients with migraine, clinician specialty had no impact on preventive prescription, with small differences observed in the choice of tricyclic antidepressants.
A recent study assessing TAK-861, an orexin-type 2 receptor agonist, high and lose doses of the therapy demonstrated improvements in wakefulness compared with the placebo in healthy adult men.
Results showed that the relative reduction (RR) in CDR-SB at end-of-study was moderately correlated with difference between treated and placebo in Centiloid change.
START will assess the potential of delaying non–vitamin K oral anticoagulant therapy following stroke related to atrial fibrillation in a large cohort of patients
Here's some of what is coming soon to NeurologyLive® this week.
The group continues discussion about patient communication needs, and Sarah Anderson, PharmD, shares resources that the National MS Society offers to both patients and providers. [WATCH TIME: 9 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is ataxias.
A group of sleep experts discuss the importance of timely and accurate diagnosis, recent approvals, and available treatment options for managing a chronic disorder and its symptoms.
As part of our monthly clinician spotlight, NeurologyLive® highlighted stroke expert Laura K Stein, MD, MPH, assistant professor of neurology at the Icahn School of Medicine at Mount Sinai and attending physician at the Mount Sinai and Mount Sinai Queens Stroke Centers.
Neurology News Network for the week ending October 28, 2023. [WATCH TIME: 4 minutes]
At 40 weeks, there were no observed cases of ARIA-edema, and new microhemorrhages occurred predominantly in patients with pre-existing conditions.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 27, 2023.
Migraine science continues to deepen the understanding of its impact, even beyond the pain and associated symptoms of the individual attacks, better equipping clinicians to meet their patients where they are.
The chief executive officer of Cognito Therapeutics provided an in-depth overview of the company’s gamma sensory stimulation device, its mechanism of action, and why it serves as a promising therapy for patients with Alzheimer disease. [WATCH TIME: 5 minutes]
ACU193 treatment reduced amyloid plaques in early Alzheimer disease patients, suggesting AßOs as a viable target, with safety data and ARIA analysis presented at CTAD 2023.
Jeff Cohen, MD, and Alicyn Magruder, PharmD, BCACP, MSCS, discuss the best practices when switching to a biosimilar therapy, including patient education and when to consider an insurance appeal. [WATCH TIME: 7 minutes]
The use of focused ultrasound-mediated blood-brain barrier opening has the potential to advance neurotherapeutics in the treatment of Alzheimer disease and other progreesive neurological disorder impacted by that barrier.
With the FDA approval, vamorolone (Agamree) becomes the first-in-class dissociative steroid therapy for patients with Duchenne muscular dystrophy. Catalyst Pharmaceuticals plans to launch the treatment in the first quarter of 2024.
If in-person interventions are unavailable, remote forms of telerehabilitation may be considered as a solution with very little cost-effectiveness and an easy option for physiotherapists and patients, even if it is for a short period of time.
Patients with mild Alzheimer disease who received high doses of BIIB080 demonstrated improvement in cognitive and functional outcomes compared with placebo, supporting further investigation.
The senior vice president of clinical development at Vaccinex provided commentary on a presentation from CTAD 2023 highlighting the therapeutic potential of peptinemab, an agent that’s shown success in Huntington disease, in patients with Alzheimer disease. [WATCH TIME: 3 minutes]
New subcutaneous lecanemab considered more effective than IV for amyloid plaque removal in Alzheimer disease; FDA application planned by March 2024.
The chief executive officer at AmyriAD Therapeutics discussed the limitations of clinical trials assessing potential disease-modifying therapies for Alzhiemer disease including the lack of a diverse patient population and nonthorough clinical assessments for diagnosis. [WATCH TIME: 6 minutes]
